Announced on May 12, 2023, the FDA's approval of fezolinetant (Veozah) marks their first approval for an NK3 receptor antagonist for the treatment of vasomotor symptoms of menopause.
Morgan Petronelli
Advertisement
Articles by Morgan Petronelli
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on HCPLive
1
Treatment Selection, Adherence, and Misconceptions in Pediatric Atopic Dermatitis
2
New Topicals in Atopic Dermatitis: Evidence, Barriers, and Real-World Perspectives
3
Atacicept and Upstream Immune Targeting in IgAN With Richard Lafayette, MD
4
Enlicitide’s FDA Approval for LDL-C Reduction and the CORALreef Outcomes Trial
5